drugset / Trial / NCT05066035

Residual Paralysis and Reversal With Routine Neostigmine Versus Half-dose Sugammadex and Routine Neostigmine

NCT05066035

RandomizedParallel-groupTriple-blindTreatment

Summary

Sugammadex may prevent residual neuromuscular blockade by providing rapid reversal at the end of the operation. Our goal is to compare the half-dose use of sugammadex for reversing residual blockade after administration of neostigmine and atropine to the routine use of reversal medication.

Timeline

Start
2013-05-01
Primary completion
2016-10-01
Completion
2016-12-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Sugammadex Other / unclassified 1 mg/kg Intravenous
Comparator Neostigmine Other / unclassified 0.03 mg/kg Intravenous
Comparator Neostigmine Other / unclassified 0.05 mg/kg Intravenous